Attached files
| file | filename |
|---|---|
| EX-32.2 - EXHIBIT 32.2 - Amneal Pharmaceuticals, Inc. | exhibit322reasons.htm |
| EX-31.2 - EXHIBIT 31.2 - Amneal Pharmaceuticals, Inc. | exhibit312reasons.htm |
| EX-31.1 - EXHIBIT 31.1 - Amneal Pharmaceuticals, Inc. | exhbit311bisaro.htm |
| EX-21 - EXHIBIT 21 - Amneal Pharmaceuticals, Inc. | exhibit21.htm |
| EX-3.2.1 - EXHIBIT 3.2.1 - Amneal Pharmaceuticals, Inc. | exhibit321bylaws.htm |
| EX-3.1.1 - EXHIBIT 3.1.1 - Amneal Pharmaceuticals, Inc. | exhibit311articles.htm |
| 10-K - 10-K - Amneal Pharmaceuticals, Inc. | atlas-20173112x10xk.htm |
EXHIBIT 32.1
CERTIFICATION PURSUANT TO
18 U.S.C. SECTION 1350, AS ADOPTED PURSUANT TO
SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002
In connection with the Annual Report on Form 10-K of Atlas Holdings, Inc. (the “Company”) for the fiscal year ended December 31, 2017 (the “Report”), Paul M. Bisaro, President and Chief Executive Officer, hereby certifies, pursuant to 18 U.S.C. Section 1350, that:
(1) | The Report fully complies with the requirements of Section 13(a) or 15(d), as applicable, of the Securities Exchange Act of 1934; and |
(2) | The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company. |
March 9, 2018 | By: | /s/ Paul M. Bisaro |
Paul M. Bisaro | ||
President and Chief Executive Officer | ||
The foregoing certification is being furnished solely pursuant to 18 U.S.C. § 1350 and is not being filed as part of the Report or as a separate disclosure document.